IART
HealthcareIntegra LifeSciences Holdings Corporation
Key Drivers
- Strong gross margin
- Heavy long-term debt
- Improving quarterly EBITDA
AIAI Summary
IART has transitioned from a growth-at-any-cost med‑tech to a remediation-led turnaround where upside now hinges on successful supply‑chain fixes, delivery of the $25–30M margin program, and meaningful deleveraging rather than organic expansion. Monitor quarterly operating cash flow stability, gross‑margin recovery vs. the 200–260bps headwind, and net-debt reduction as the binary catalysts that will validate a re-rating (failure raises refinancing/asset-sale risk).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Heavy long-term debt
- •Improving quarterly EBITDA
Iovance combines strong gross margins, improving recent quarterly profitability and adequate short-term liquidity with persistent annual losses, very high long-term debt and negative returns that make its equity undervalued but risky.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Deeply oversold
- •Near-term support
Over the last month the stock shows a clear short-term downtrend (roughly a 25% drop from late Feb to 2026-03-20), is deeply oversold by momentum and holding a near-term support around $8.90–$8.95 while facing layered resistance at ~$10.40 and $11.30–$12.20.
~25% decline from late
Sentiment & News
Key News Insights:
- •Margin pressure
- •Tight liquidity
- •Product-driven growth
Integra LifeSciences beat Q4 revenue and EPS but faces margin pressure, sales softness and tight liquidity while relying on Codman demand and international launches for modest 2026 growth.
The mixed results and cautious 2026 guidance likely limit near-term upside for the stock but leave scope for recovery if Codman and international expansion sustain revenue momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings